Clinical Trials

Arcutis ARQ-151-315 Pediatric Atopic Dermatitis

A 4-Week, Double Blind, Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis (ARQ-151-315)

Physician & Study Coordinator

Physician

Andrew Krakowski, MD

Study Coordinators

Heather Herbold
484-658-1798
Heather.Herbold@sluhn.org

Synopsis

This study is being done to evaluate the safety and efficacy of ARQ-151 cream in children with mild to moderate eczema (atopic dermatitis) after application once every day for a month.

Eligibility Criteria

Informed consent by parent(s) or legal guardian as required by local laws
Males and females, ages 2 to 5 years old at time of signing Informed Consent (Screening) and at Baseline (Day 1)
Diagnosed with atopic dermatitis for at least 6 weeks, as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening
In good health as judged by the Investigator